Journal of Urban Health

, Volume 81, Issue 4, pp 719–734 | Cite as

Co-occurring hepatitis C, substance use, and psychiatric illness: Treatment issues and developing integrated models of care

  • Diana L. Sylvestre
  • Jennifer M. Loftis
  • Peter Hauser
  • Sander Genser
  • Helen Cesari
  • Nicolette Borek
  • Thomas F. Kresina
  • Leonard Seeff
  • Henry Francis
Article

Abstract

Hepatitis C virus (HCV) infection is transmitted by injection drug use and associated with psychiatric conditions. Patients with drug use or significant psychiatric illness have typically been excluded from HCV treatment trials noting the 1997 National Institutes of Health Consensus Statement on HCV that indicated active drug use and major depressive illness were contraindications to treatment of HCV infection. However, the 2002 NIH Consensus Statement recognized that these patients could be effectively treated for HCV infection and recommended that treatment be considered on a case-by-case basis. Treating HCV infection in these patients is challenging, with drug use relapse possibly leading to psychosocial instability, poor adherence, and HCV reinfection. Interferon therapy may exacerbate preexisting psychiatric symptoms. Co-occurring human immunodeficiency virus or hepatitis B virus provide additional challenges, and access to ancillary medical and psychiatric services may be limited. Patients with co-occurring HCV infection, substance use, and psychiatric illness can complete interferon treatment with careful monitoring and aggressive intervention. Clinicians must integrate early interventions for psychiatric conditions and drug use into their treatment algorithm. Few programs or treatment models are designed to manage co-occurring substance use, psychiatric illness, and HCV infection and therapy. The National Institute on Drug Abuse convened a panel of experts to address the current status and the long-range needs through a 2-day workshop, Co-occurring Hepatitis C, Substance Abuse, and Psychiatric Illness: Addressing the Issues and Developing Integrated Models of Care. This conference report summarizes current data, medical management issues, and strategies discussed.

Keywords

Comorbidities HIV HCV Psychiatric illness Treatment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hoofnagle JH, Tralka TS. Introduction: The National Institutes of Health Consensus Development conference: management of hepatitis C. Hepatology. 1997;26(suppl 1):1S.Google Scholar
  2. 2.
    Seeff LB, Hoofnagle JH Appendix: the National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis. 2003;7:261–287.CrossRefPubMedGoogle Scholar
  3. 3.
    Sherman KE. Implications of peginterferon use in special populations infected with HCV. Semin Liver Dis. 2003;23(suppl 1):47–52.PubMedGoogle Scholar
  4. 4.
    Zeuzem S, Heathcote EJ, Shiffman ML, et al. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol. 2003;39:106–111.CrossRefPubMedGoogle Scholar
  5. 5.
    Community Epidemiology Work Group. Epidemiologic trends in drug abuse. In: Proceedings of the Community Epidemiology Work Group December 2001 ed. Moira O’Brian. Vol. 1. Bethesda, MD: National Institute on Drug Abuse, NIH, DHHS; 2002: 1–68. NIH Publication 02-5109.Google Scholar
  6. 6.
    Patrick DM, Buxton JA, Bigham M, Mathias RG. Public health and hepatitis C. Can J Public Health. 2000;91(suppl 1):S18–S23.PubMedGoogle Scholar
  7. 7.
    McCarthy JJ, Flynn N. Hepatitis C in methadone maintenance patients: prevalence an public policy implications. J Addict Dis. 2001;20:19–31.CrossRefPubMedGoogle Scholar
  8. 8.
    Quaglio G, Lugoboni F, Pajusco B et al. Facors associated with hepatitis C virus infection in injection and noninjection drug users in Italy. Clin Infect Dis. 2003;37:33–40.CrossRefPubMedGoogle Scholar
  9. 9.
    Hagan H, Des Jarlais DC. HIV and HCV infection among injection drug users. Mount Sinai J Med. 2000;67:423–428.Google Scholar
  10. 10.
    Osher FC, Goldberg RW, McNary SW, Essock SM, Butterfield MI, Rosenberg SD, Substance abuse and the transmission of hepatitis C among persons with severe mental illness. Psychiatr Serv. 2003;54:842–847.CrossRefPubMedGoogle Scholar
  11. 11.
    Klinkenberg WD, Caslyn RJ, Morse GA, et al. Prevalence of human immunodeficiency virus, hepatitis B, and hepatitis C among homeless persons with co-occurring severe mental illness and substance use disorders. Compr Psychiatry. 2003;44:293–302.CrossRefPubMedGoogle Scholar
  12. 12.
    Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology. 2000;31:1207–1211.CrossRefPubMedGoogle Scholar
  13. 13.
    Forton MD, Taylor-Robinson SD, Thomas HC. Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat. 2003;10:81–86.CrossRefPubMedGoogle Scholar
  14. 14.
    Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry. 1999;156:1120–1129.PubMedGoogle Scholar
  15. 15.
    Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet. 1999;354:131–132.CrossRefPubMedGoogle Scholar
  16. 16.
    DiClemente CC, Carbonari JP, Montgomery RP, Hughes SO. The Alcohol Abstinence Self-Efficacy scale. J Stud Alcohol. 1994;55:141–148.PubMedGoogle Scholar
  17. 17.
    McLellan AT, Luborsky L, Woody GE, O’Brien CP. An improved diagnostic instrument for substance abuse patients: the Addiction Severity Index. J Nerv Mental Dis. 1980;168:26–33.Google Scholar
  18. 18.
    WHO ASSIST Working Group. The WHO Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction. 2002;97:1183–1194.CrossRefGoogle Scholar
  19. 19.
    Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro M. AUDIT—the Alcohol Use Disorders Identification Test: guidelines for use in primary health care. World Health Organization, Department of Mental Health and Substance Abuse, 2001. Accessed September 3, 2004. Available at: http://www.who.int/substance_abuse/PDFfiles/auditbro.pdf.Google Scholar
  20. 20.
    Bradley KA, Bush K, Dobie DJ, et al. Two brief alcohol-screening tests from the Alcohol Use Disorders Identification Test (AUDIT): validation in a female Veterans Affairs patient population. Arch Intern Med. 2003;163:821–829.CrossRefPubMedGoogle Scholar
  21. 21.
    Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol. 1995;56:423–432.PubMedGoogle Scholar
  22. 22.
    Reinert DF, Allen JP. The alcohol Use Disorders Identification Test (AUDIT): a review of recent research. Alcohol Clin Exp Res. 2002;26:272–279.CrossRefPubMedGoogle Scholar
  23. 23.
    Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med. 1998;158:1789–1795.CrossRefPubMedGoogle Scholar
  24. 24.
    Drake RE, Essock SM, Shaner A, et al. Implementing dual diagnosis services for clients with severe mental illness. Psychiatr Serv. 2001;52:469–476.CrossRefPubMedGoogle Scholar
  25. 25.
    Svanborg PM, Asberg M. A comparison between the Beck Depression Inventory (BDI) and the self-rating version of the Montgomery Asberg Depression Rating Scale (MADRS). J Affect Disord. 2001;64:203–216.CrossRefPubMedGoogle Scholar
  26. 26.
    Beck AT, Steer RA, Ball R. Comparison of Beck Depression Inventories-IA and II in psychiatric outpatients. J Pers Assess. 1996;67:588–597.CrossRefPubMedGoogle Scholar
  27. 27.
    Flemenbaum A, Zimmermann RL. Inter- and intra-rater reliability of the Brief Psychiatric Rating Scale. Psychol Rep. 1973;32:783–792.PubMedGoogle Scholar
  28. 28.
    NIAAA. Helping Patients with alcohol problems: a health practitioners guide. January 2003. NIH Publication 03-3769. Accessed September 3, 2004. Available at: http://www.niaaa.nih.gov/publications/Practitioner/HelpingPatients.htm.Google Scholar
  29. 29.
    Fiellin DA, Reid MC, O’Connor PG: Screening for alcohol problems in primary care. Arch Intern Med. 2000;160:1977–1989.CrossRefPubMedGoogle Scholar
  30. 30.
    Brown RL, Rounds LA. Conjoint screening questionnaires for alcohol and other drug abuse: criterion validity in primary care practice. Wisc Med J. 1995;94:135–140.Google Scholar
  31. 31.
    Gavin DR, Ross HE, Skinner HA. Diagnostic validity of the drug abuse screening test in the assessment of DSM-III drug disorders. Br J Addict. 1980;84:301–307.CrossRefGoogle Scholar
  32. 32.
    Rumpf H-J, Hapke H, Meyer C, John U. Screening for alcohol use disorders and at-risk drinking in the general population: psychometric performance of three questionnaires. Alcohol Alcohol. 2002;37:261–268.PubMedGoogle Scholar
  33. 33.
    Deployment Health Clinical Center. PTSD Checklist—Military Version (PCL-M). Accessed September 3, 2004. Available at: www.pdhealth.mil/guidelines/appendix4.asp.Google Scholar
  34. 34.
    Brown RL, Leonard T, Saunders LA, Papasouliotis O. A two-item conjoint screen for alcohol and other drug problems. J Am Board Fam Pract. 2001;14:95–106.PubMedGoogle Scholar
  35. 35.
    Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;33:429–435.CrossRefGoogle Scholar
  36. 36.
    Zung WW, Wonnacott TH. Treatment prediction in depression using a self-rating scale. Biol Psychiatry. 1970;2:321–329.PubMedGoogle Scholar
  37. 37.
    Beck AT, Ward C, Mendelson M, Mock JE, Erbaugh JK. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571.PubMedGoogle Scholar
  38. 38.
    Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics. 2003;44:104–112.CrossRefPubMedGoogle Scholar
  39. 39.
    Wright IA. Monitoring depression in patients undergoing alpha-interferon and ribavirin therapy for hepatitis C. Gastroenterol Nurs. 2000;23:275–280.CrossRefPubMedGoogle Scholar
  40. 40.
    Bean P. Update on new biomarkers for detecting excessive alcohol use. AlcoholMD.com Web site. November 2002. Available at: http://www.alcoholmd.com/pro/courses/biomarkers_of_alcohol_abuse.asp.Google Scholar
  41. 41.
    Wolff K, Farrell M, Marsden J. A review of biological indicators of illicit drug use: practical considerations and clinical usefulness. Addiction. 1999;94:1279–1298.CrossRefPubMedGoogle Scholar
  42. 42.
    Portland VA Medical Center, Mood Disorders Center. Patient Screening Questions (PSQ). Accessed September 3, 2004. Available at: www.portland.me.va.gov/mood-disorders-center.Google Scholar
  43. 43.
    Martin EM, Pitrak DL, Novak RM, Pursell KJ, Mullane KM. Reaction times are faster in HIV-seropositive patients on antiretroviral therapy: a preliminary report. J Clin Exp Neuropsychol. 1999;21:730–735.PubMedGoogle Scholar
  44. 44.
    Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology. 2002;35:440–446.CrossRefPubMedGoogle Scholar
  45. 45.
    Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 2002;35:433–439.CrossRefPubMedGoogle Scholar
  46. 46.
    Ernst T, Chang L, Jovicich J, Ames N, Arnold S. Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology. 2002;59:1343–1349.PubMedGoogle Scholar
  47. 47.
    Martin EM, Novak RM, Fendrich M, et al. Stroop performance in drug users classified by HIV and hepatitis C virus serostatus. J Int Neurophysiol Soc. 2004;10:298–300.CrossRefGoogle Scholar
  48. 48.
    Stephenson J. Former addicts face barriers to treatment for HCV. JAMA. 2001;285: 1003–1005.CrossRefPubMedGoogle Scholar
  49. 49.
    Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med. 2001;345:215–217.CrossRefPubMedGoogle Scholar
  50. 50.
    Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users. N Engl J Med. 2001;345:211–214.CrossRefPubMedGoogle Scholar
  51. 51.
    Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology. 2001;34:188–193.CrossRefPubMedGoogle Scholar
  52. 52.
    Ho SB, Nguyen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E. Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol. 2001;96:157–164.PubMedGoogle Scholar
  53. 53.
    Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend. 2002;67:117–123.CrossRefPubMedGoogle Scholar
  54. 54.
    Dalgard O, Bjoro K, Hellum K, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years’ follow-up. Eur Addict Res. 2002;8:45–49.CrossRefPubMedGoogle Scholar
  55. 55.
    Van Thiel D, Friedlander L, Molloy P, Fagiuoli S, Kania R, Caraceni P. Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol. 1995;7:165–168.PubMedGoogle Scholar
  56. 56.
    Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7:942–947.CrossRefPubMedGoogle Scholar
  57. 57.
    San Francisco and Miami Centers of excellence in Hepatitis C Research and Education and the Hepatitis C Technical Advisory Group DoVA. Treatment Recommendations for Patients With Chronic Hepatitis C. Version 1.0. Washington, DC: Veteran’s Health Administration, Department of Veterans’ Affairs; 2002.Google Scholar
  58. 58.
    Levenson J, Fallon H. Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol. 1993;88:760–761.PubMedGoogle Scholar
  59. 59.
    Gleason O, Yates W. Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics. 1999;40:510–512.PubMedGoogle Scholar
  60. 60.
    Schramm T, Lawford B, Macdonald G, Cooksley W. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust. 2000;173:359–361.PubMedGoogle Scholar
  61. 61.
    Loftis J, Socherman RE, Whitehead AJ, Hauser P. Interferon-alpha-induced depression: time course and antidepressant response of symptom dimensions for patients with hepatitis C. Psychosom Med. In press.Google Scholar
  62. 62.
    Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 2002;26:643–652.CrossRefPubMedGoogle Scholar
  63. 63.
    Pettinati HM. The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes. J Clin Psychiatry. 2001;62:26–31.PubMedGoogle Scholar
  64. 64.
    Naranjo CA, Knoke DM. The role of selective serotonin reuptake inhibitors in reducing alcohol consumption. J Clin Psychiatry. 2001;62:18–25.PubMedGoogle Scholar
  65. 65.
    Srisurapanont M, Kittiratanapaiboon P, Jarusuraisin N. Treatment for amphetamine psychosis. Cochrane Database Syst Rev. 2001:CD003026.Google Scholar
  66. 66.
    McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284:1689–1695.CrossRefPubMedGoogle Scholar
  67. 67.
    Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science. 1988;242:715–723.PubMedGoogle Scholar
  68. 68.
    Wise RA, Bozarth MA. Brain substrates for reinforcement and drug self-administration. Prog Neuropsychopharmacol. 1981;5:467–474.CrossRefPubMedGoogle Scholar
  69. 69.
    Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Brain Res Rev. 1991;16:223–244.CrossRefPubMedGoogle Scholar
  70. 70.
    Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev. 1993;18:247–291.CrossRefPubMedGoogle Scholar
  71. 71.
    Kreek MJ, Koob GF. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend. 1998;51:23–47.CrossRefPubMedGoogle Scholar
  72. 72.
    Stimmel B, Kreek MJ. Neurobiology of addictive behaviors and its relationship to methadone maintenance. Mt Sinai J Med. 2000;67:375–380.PubMedGoogle Scholar
  73. 73.
    Nestler EJ, Hope BT, Widnell KL. Drug addiction: a model for the molecular basis of neural plasticity. Neuron. 1993;11:995–1006.CrossRefPubMedGoogle Scholar
  74. 74.
    Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry. 2002;7:468–473.CrossRefPubMedGoogle Scholar
  75. 75.
    Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol. 2002;22:86–90.CrossRefPubMedGoogle Scholar
  76. 76.
    Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3 dioxygenase, and tryptophan catabolism. FASEB J. 1991;5:2516–2522.PubMedGoogle Scholar
  77. 77.
    Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune disease and AIDS. Adv Exp Med Biol. 1991;294:425–435.PubMedGoogle Scholar
  78. 78.
    Boyer P. Do anxiety and depression have a common pathophysiological mechanism. Acta Psychiatr Scand Suppl. 2000;406:24–29.CrossRefPubMedGoogle Scholar
  79. 79.
    Leonard BE, Song C. Changes in the immune system in rodent models of depression. Int J Neuropsychopharmacol. 2002;5:345–356.CrossRefPubMedGoogle Scholar
  80. 80.
    Jones TH, Wadler S, Hupart KH. Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha. Semin Oncol. 1998;25(suppl 1):54–63.PubMedGoogle Scholar
  81. 81.
    Pollak Y, Yirmiya R. Cytokine-induced changes in mood and behavior: implications for “depression due to a general medical condition,” immunotherapy and antidepressive treatment. Int J Neuropsychopharmacol. 2002;5:389–399.CrossRefPubMedGoogle Scholar
  82. 82.
    Bonaccorso S, Puzella A, Marino V, et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res. 2001;105:45–55.CrossRefPubMedGoogle Scholar
  83. 83.
    Foucart S, Abadie C. Interleukin-1 beta and tumor necrosis factor-alpha inhibit the release of 3H-noradrenaline form mice isolated atria. Naunyn Schmiedebergs Arch Pharmacol. 1996;354:1–6.CrossRefPubMedGoogle Scholar
  84. 84.
    Dunn AJ. Effects of the IL-1 receptor antagonist on the IL-1 and exotoxin-induced activation of the HPA axis and cerebral biogenic amines in mice. Neuroimmunomodulation. 2000;7:36–45.CrossRefPubMedGoogle Scholar
  85. 85.
    Parker KJ, Schatzberg AF, Lyons DM. Neuroendocrine aspects of hypercortisolism in major depression. Horm Behav. 2003;43:60–66.CrossRefPubMedGoogle Scholar
  86. 86.
    Spaulding A, Lau D, Weinbaum C, et al. Developing a framework for correctional management of hepatitis C. A review of current and future management of the disease in prisons. In press.Google Scholar
  87. 87.
    Drake RE, Mercer-McFadden C, Mueser KT, McHugo GJ, Bond GR. Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophr Bull. 1998;24:589–608.PubMedGoogle Scholar
  88. 88.
    Druss BG, Rohrbaugh RM, Levinson CM, Rosenheck RA. Integrated medical care for patients with serious psychiatric illness: a randomized trial. Arch Gen Psychiatry. 2001; 58:861–868.CrossRefPubMedGoogle Scholar
  89. 89.
    Phillips SD, Burns BJ, Edgar ER, et al. Moving assertive community treatment into standard practice. Psychiatr Serv. 2001;52:771–779.CrossRefPubMedGoogle Scholar

Copyright information

© The New York Academy of Medicine 2004

Authors and Affiliations

  • Diana L. Sylvestre
    • 1
  • Jennifer M. Loftis
    • 2
    • 3
  • Peter Hauser
    • 2
    • 3
  • Sander Genser
    • 4
  • Helen Cesari
    • 4
  • Nicolette Borek
    • 4
  • Thomas F. Kresina
    • 4
  • Leonard Seeff
    • 5
  • Henry Francis
    • 4
  1. 1.Department of MedicineUniversity of CaliforniaSan FranciscoUSA
  2. 2.School of MedicineOregon Health and Sciences UniversityUSA
  3. 3.Portland VA Medical CenterNorthwest Hepatitis C Resource CenterUSA
  4. 4.Center for AIDS and Other Medical Consequences of Drug AbuseNational Institute on Drug Abuse, National Institutes of HealthUSA
  5. 5.National Institute of Diabetes Digestive and Kidney DiseasesNational Institutes of HealthUSA

Personalised recommendations